GlassScriptPhysician profile
Charles Gober
NPI 1083233266
$578.10
in general payments reported to CMS, 2019-2025
14 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $24.22 · 2023: $54.45 · 2024: $138 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $553.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $94.20 | 2025 | Freestyle Libre 3 |
| Pfizer INC. | $71.48 | 2023-2025 | |
| Amgen INC. | $57.54 | 2023-2024 | Prolia, Evenity |
| Glaxosmithkline, LLC. | $49.49 | 2023-2025 | Shingrix, Arexvy |
| Dexcom, INC. | $46.88 | 2024-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $42.94 | 2025 | Inspire |
| Medtronic, INC. | $41.90 | 2025 | Venaseal, Inceptiv |
| Merck Sharp & Dohme LLC | $38.96 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Daiichi Sankyo INC. | $28.05 | 2024 | Injectafer |
| Agios Pharmaceuticals, INC. | $25.64 | 2025 | Pyrukynd |
| Regeneron Healthcare Solutions, INC. | $24.22 | 2022 | |
| Boston Scientific Corporation | $21.38 | 2025 | Wavewriter Alpha Prime 16 |
| Sanofi Pasteur INC. | $20.78 | 2025 | |
| Lilly USA, LLC | $14.64 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Gober listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.